Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
2.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
5.
6.

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.

Rosenheck R, Doyle J, Leslie D, Fontana A.

Schizophr Bull. 2003;29(1):81-93.

PMID:
12908663
7.
8.

Clozapine eligibility among state hospital patients.

Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L.

Schizophr Bull. 1996;22(1):15-25.

PMID:
8685657
9.

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

Essock SM, Hargreaves WA, Covell NH, Goethe J.

Psychopharmacol Bull. 1996;32(4):683-97.

PMID:
8993092
10.
11.

Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.

Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR.

Can J Clin Pharmacol. 2001 Winter;8(4):199-206.

PMID:
11743592
12.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
13.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
14.

Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.

Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J.

J Ment Health Policy Econ. 2004 Jun;7(2):77-85.

PMID:
15208468
16.

[Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].

Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH, Cornet-Bonnefont M, Robert H.

Encephale. 1997 Sep;23 Spec No 4:24-31. French.

PMID:
9417402
17.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
18.

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.

Revicki DA.

J Clin Psychiatry. 1999;60 Suppl 1:7-11; discussion 28-30. Review.

19.

Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Ginsberg G, Shani S, Lev B.

Pharmacoeconomics. 1998 Feb;13(2):231-41.

PMID:
10178649
20.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216

Supplemental Content

Support Center